Extension CombiRx Data Show No Benefit of Combined MS DrugsExtension CombiRx Data Show No Benefit of Combined MS Drugs

Seven-year results of a large trial comparing a combination of interferon-beta1a and glatiramer acetate to monotherapy with either drug alone continue to show no additional benefit of the combination therapy. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news